"Bruno Strigini is the Chief Executive Officer at Novartis Oncology, one of the first companies to form a global business unit dedicated to developing and launching innovative oncology medicines that address the unmet medical needs of people with cancer and related diseases. Today, Bruno oversees more than 10,000 associates in 85 countries working to transform cancer care and address some of society’s most challenging healthcare issues through science-based innovation. Bruno joined Novartis in June 2014 as President of Oncology. Prior to Novartis, he was president of MSD for Europe and Canada (Merck & Co. Inc. in the United States and Canada). He previously worked at Schering-Plough, UCB Celltech and SmithKline Beecham, and his roles included president of international operations, president of Japan and Asia-Pacific, head of global marketing and business development, and managing director positions. Bruno holds a Master of Business Administration from IMD in Switzerland, a Doctor of Pharmacy from the University of Montpellier in France, and a master’s degree in microbiology from Heriot-Watt University in the United Kingdom. Since 2012, he has been a member of the Académie Nationale de Pharmacie in France, and in 2014 he was awarded a doctor honoris causa from Universidad Internacional Menendez Pelayo in Spain."